Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) FCF Margin (2016 - 2024)

Historic FCF Margin for Summit Therapeutics (SMMT) over the last 7 years, with Q2 2024 value amounting to 1065.93%.

  • Summit Therapeutics' FCF Margin changed N/A to 1065.93% in Q2 2024 from the same period last year, while for Sep 2025 it was 1.45047488036864e19%, marking a year-over-year decrease of 1.4504748803686405e23%. This contributed to the annual value of 5986.67% for FY2022, which is 19572000.0% down from last year.
  • As of Q2 2024, Summit Therapeutics' FCF Margin stood at 1065.93%.
  • Summit Therapeutics' FCF Margin's 5-year high stood at 2639.53% during Q1 2020, with a 5-year trough of 3879.55% in Q3 2022.
  • For the 3-year period, Summit Therapeutics' FCF Margin averaged around 197.89%, with its median value being 1015.79% (2024).
  • Data for Summit Therapeutics' FCF Margin shows a peak YoY increase of 4963300bps (in 2020) and a maximum YoY decrease of 4963300bps (in 2020) over the last 5 years.
  • Over the past 3 years, Summit Therapeutics' FCF Margin (Quarter) stood at 2639.53% in 2020, then tumbled by -247bps to 3879.55% in 2022, then surged by 127bps to 1065.93% in 2024.
  • Its FCF Margin stands at 1065.93% for Q2 2024, versus 965.65% for Q1 2024 and 3879.55% for Q3 2022.